StockNews.com has downgraded Bio-Rad Laboratories (NYSE:BIO) to “Hold.”
In a note that was distributed to shareholders on Wednesday, the equity research analysts at StockNews.com downgraded their recommendation for ...
Tag: BIO, Analyst Rating
Mitsubishi UFJ Kokusai Asset Management Co. Ltd. expands its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO)
According to the most recent Form 13F filing that Mitsubishi UFJ Kokusai Asset Management Co. Ltd. made with the SEC, ...
StockNews.com has downgraded Bio-Rad Laboratories (NYSE:BIO) to “Hold.”
In a note that was distributed to shareholders on Wednesday, the equity research analysts at StockNews.com downgraded their recommendation for ...
According to the company’s most recent 13F filing with the Securities and Exchange Commission, SG Americas Securities LLC increased its holdings of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 553.5% in the third quarter. After acquiring an additional 3,188 shares during the period, the institutional investor now owns 3,764 shares of the medical research company’s stock. At the end of the most recent reporting period, SG Americas Securities LLC’s holdings in Bio-Rad Laboratories were worth $1,570,000.
Recent transactions involving other significant investors involved the buying and selling business stock. These transactions occurred recently. During the second ...
Pinnacle Financial Partners Inc. invests in Bio-Rad Laboratories, Inc. (NYSE:BIO)
Pinnacle Financial Partners Inc. increased its holdings in Bio-Rad Laboratories, Inc. (NYSE: BIO), as stated in the most recent 13F ...
Short interest in Bio-Rad Laboratories, Inc. (NYSE:BIO) fell 30.3% in November.
The total amount of short interest in Bio-Rad Laboratories, Inc., saw a sizeable drop in November after the company reported ...
Coverage of Bio-Rad Laboratories Begins at the Royal Bank of Canada
According to The Fly, the Royal Bank of Canada assumed coverage on shares of Bio-Rad Laboratories in a research note ...
The latest information on short interest for Bio-Rad Laboratories Inc.
November saw a substantial increase in short interest for Bio-Rad Laboratories, Inc. (NYSE: BIO). As of November 15th, 284,100 shares ...
Bio-Rad Laboratories (NYSE:BIO) reports earnings, exceeding expectations by $0.01 per share.
On Thursday, the report of earnings for the prior quarter was made public by Bio-Rad Laboratories, which trades under the ...
Credit Suisse Group lowers its price target for Bio-Rad Laboratories (NYSE:BIO) to $640.00.
In a report released on Friday by Stock Target Advisor, equity analysts at Credit Suisse Group lowered their price target ...
